Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:24:53 EDT Wed 01 May 2024
Enter Symbol
or Name
USA
CA



News for U:VRTX from 2023-05-02 to 2024-05-01 - 51 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-23 00:45U:VRTXNews ReleaseVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
2024-04-18 08:00U:VRTXNews ReleaseVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
2024-04-10 16:01U:VRTXNews ReleaseVertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-10 16:01U:VRTXNews ReleaseVertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-09 16:05U:VRTXNews ReleaseVertex to Announce First Quarter 2024 Financial Results on May 6
2024-04-01 11:00U:VRTXNews ReleaseVertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-04-01 11:00U:VRTXNews ReleaseVertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-04-01 08:00U:VRTXNews ReleaseVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
2024-03-21 08:00U:VRTXNews ReleaseVertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2024-02-20 16:05U:VRTXNews ReleaseVertex to Participate in Upcoming Investor Conferences
2024-02-13 01:59U:VRTXNews ReleaseEuropean Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-02-05 16:06U:VRTXNews ReleaseVertex Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-05 16:01U:VRTXNews ReleaseVertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
2024-01-30 06:28U:VRTXNews ReleaseVertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
2024-01-17 08:00U:VRTXNews ReleaseVertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
2024-01-16 14:24U:VRTXNews ReleaseVertex Announces US FDA Approval of CASGEVY ¢ „ ¢ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
2024-01-09 12:42U:VRTXNews ReleaseVertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
2024-01-07 15:00U:VRTXNews ReleaseVertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
2023-12-18 16:05U:VRTXNews ReleaseVertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
2023-12-15 08:12U:VRTXNews ReleaseVertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-12-13 06:30U:VRTXNews ReleaseVertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
2023-12-11 19:30U:VRTXNews ReleasePositive Results from Pivotal Trials of CASGEVY ¢ „ ¢ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
2023-12-08 12:52U:VRTXNews ReleaseVertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY ¢ „ ¢ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
2023-12-05 16:01U:VRTXNews ReleaseVertex Appoints Nancy Thornberry to its Board of Directors
2023-11-29 13:59U:VRTXNews ReleaseHealth Canada Grants Market Authorization for KALYDECO ® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
2023-11-29 13:59U:VRTXNews ReleaseHealth Canada Grants Market Authorization for KALYDECO ® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older
2023-11-23 09:05U:VRTXNews ReleaseEuropean Commission Approves KAFTRIO ‚ ® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
2023-11-16 01:45U:VRTXNews Release ‚  Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemi
2023-11-06 16:01U:VRTXNews ReleaseVertex Reports Third Quarter 2023 Financial Results
2023-11-02 09:02U:VRTXNews ReleaseVertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
2023-11-02 08:30U:VRTXNews ReleaseVertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA ‚ ® at the North American Cystic Fibrosis Conference
2023-10-26 08:00U:VRTXNews ReleaseVertex to Present at Upcoming Investor Conferences
2023-10-17 14:44U:VRTXNews ReleaseHealth Canada Grants Market Authorization for TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
2023-10-17 14:44U:VRTXNews ReleaseHealth Canada Grants Market Authorization for TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation
2023-10-10 08:00U:VRTXNews ReleaseVertex to Announce Third Quarter 2023 Financial Results on November 6
2023-10-05 08:00U:VRTXNews ReleaseVertex Appoints Michel Lagarde to its Board of Directors
2023-10-03 18:01U:VRTXNews ReleaseVertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
2023-09-15 08:52U:VRTXNews ReleaseVertex Receives CHMP Positive Opinion for KAFTRIO ‚ ® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
2023-09-14 09:15U:VRTXNews ReleaseVertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
2023-08-30 16:01U:VRTXNews ReleaseVertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
2023-08-29 09:00U:VRTXNews ReleaseVertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
2023-08-03 08:00U:VRTXNews ReleaseVertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
2023-08-01 16:01U:VRTXNews ReleaseVertex Reports Second Quarter 2023 Financial Results
2023-06-30 08:01U:VRTXNews ReleaseVertex to Announce Second Quarter 2023 Financial Results on August 1
2023-06-26 07:30U:VRTXNews ReleaseVertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
2023-06-23 18:55U:VRTXNews ReleaseVertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
2023-06-09 11:00U:VRTXNews ReleaseVertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
2023-06-09 03:01U:VRTXNews ReleasePositive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
2023-06-08 19:23U:VRTXNews ReleaseFDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-05-30 08:01U:VRTXNews ReleaseVertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
2023-05-03 17:07U:VRTXNews ReleaseVertex Announces U.S. FDA Approval for KALYDECO ‚ ® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older